Of the seven drugmakers that reported earnings by Oct. 29, Pfizer, Merck, Johnson & Johnson, Roche, Novartis and AstraZeneca all beat sales expectations, while Eli Lilly fell short by $20 million.
AstraZeneca, Novartis and Roche benefited from new drug sales, while Merck and Pfizer benefited from sales of their specialty cancer drugs, Keytruda and Ibrance.
The third-quarter growth comes as Congress debates legislation the drug industry’s largest lobbying group has referred to as “nuclear winter.”
Other large drugmakers like GlaxoSmithKline, Sanofi and AbbVie are all scheduled to report earnings later this week.
Read the full article here.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Centura Health opens retail pharmacy
Six of the world’s largest drugmakers reported third quarter earnings that exceeded Wall Street’s expectations, according to BioPharma Dive.
Of the seven drugmakers that reported earnings by Oct. 29, Pfizer, Merck, Johnson & Johnson, Roche, Novartis and AstraZeneca all beat sales expectations, while Eli Lilly fell short by $20 million.
AstraZeneca, Novartis and Roche benefited from new drug sales, while Merck and Pfizer benefited from sales of their specialty cancer drugs, Keytruda and Ibrance.
The third-quarter growth comes as Congress debates legislation the drug industry’s largest lobbying group has referred to as “nuclear winter.”
Other large drugmakers like GlaxoSmithKline, Sanofi and AbbVie are all scheduled to report earnings later this week.
Read the full article here.
